BioCardia has patented a method to screen patients with chronic myocardial ischemia or heart failure to determine the suitability of their bone marrow cells for transplantation. The method involves assessing CD19+, CD34+, or CD133+ cell concentrations in a blood sample to identify cells suitable for transplantation without enriching specific populations. GlobalData’s report on BioCardia gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCardia, Shapeable guide catheters was a key innovation area identified from patents. BioCardia's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Screening method for autologous bmc transplantation in heart disease
A recently granted patent (Publication Number: US11828757B2) outlines a method for screening patients with chronic myocardial ischemia or heart failure of ischemic etiology to determine the suitability of their autologous bone marrow cells (BMC) for transplantation to a different tissue site to treat the condition. The method involves using a cell counter to assess the concentrations of specific cell types (CD19+, CD34+, or CD133+) in the patient's blood sample, with threshold concentrations indicating suitability for transplantation without enriching specific phenotypic populations of BMC. The identified BMC are then transplanted to the tissue site without further enrichment, potentially offering a novel approach to treating chronic myocardial ischemia or heart failure of ischemic etiology.
Furthermore, the patent details various aspects of the method, including specific threshold concentrations for CD19+, CD34+, or CD133+ cells in the BMC, methods for providing the BMC dosage, and different techniques for transplanting the cells to the tissue site. The method allows for customization based on individual patient profiles and offers potential applications such as intra-myocardial injection or surgical implantation of the autologous BMC to treat chronic myocardial ischemia or heart failure of ischemic etiology. By focusing on specific cell concentrations and avoiding the enrichment of particular phenotypic populations, this method may provide a targeted and effective treatment option for patients with these conditions, potentially improving outcomes and quality of life.
To know more about GlobalData’s detailed insights on BioCardia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
